Aditxt raises $1M in senior notes, invests $925K in Evofem; CEO targets Evofem close by Sept 2025

Aditxt, Inc.

Issued $1M senior notes (10% interest, maturity Sept 30, 2025) at $800K purchase price (20% original issue discount).
Purchased $1.42M Evofem convertible note and warrant for $925K; convertible at $0.0154/share, warrant exercisable for 5 years.
Evofem reported ~$20M revenue in 2024; CEO says pending acquisition target close by end of September 2025, subject to shareholder approval.
Pearsanta near commercialization (end 2025/Q1 2026) for prostate cancer and endometriosis tests using mitochondrial DNA.
Adimune autoimmune therapeutic platform still early stage; described as 'sleeping giant'; retraining immune system approach.

item 1.01item 2.03item 3.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.